Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Tiyou, Ayele ^a   Belachew, Tefera ^a   Alemseged, Fisehaye ^a   Biadgilign, Sibhatu ^a  

^a JIMMA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NIVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ETHIOPIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; SOCIAL SUPPORT;

EID: 77958525884     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-39     Document Type: Article

References (49)

1. UNAIDS/WHO AIDS epidemic update. 2009, UNAIDS/09.36E/JC1700E, UNAIDS/WHO.
2. World Health Organization Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: Towards universal access. Recommendations for a public health approach 2006, World Health Organization.
3. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005, 191:339-47. 10.1086/427192, 15633092.
4. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002, 185(suppl 2):S143-51. 10.1086/340197, 12001036.
5. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 2005, 19(12):1243-9. 10.1097/01.aids.0000180094.04652.3b, 16052078.
6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis E, Squire C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
7. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in Africa. Lancet 2001, 358:410-4. 10.1016/S0140-6736(01)05551-9, 11502341.
8. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999, 29:824-30. 10.1086/520443, 10589897.
9. Haubrich RH, Little SJ, Currier JS, et al. The value of patient reported adherence to antiretroviral therapy in predicting virologic and immunologic response: California Collaborative Treatment Group. AIDS 1999, 13:1099-1107. 10.1097/00002030-199906180-00014, 10397541.
10. Paterson DL, Swindels S, Mohr JA, et al. Adherence with proteaseinhibitor therapy for human immunodeficiency virus infection. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998 1998, I-172. San Diego, California: American Society for Microbiology.
11. Kastrissios H, Suaárez J-R, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998, 12:2295-2303. 10.1097/00002030-199817000-00011, 9863872.
12. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998, 339:1261-8. 10.1056/NEJM199810293391801, 9791141.
13. Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998, 339(18):1269-76. 10.1056/NEJM199810293391802, 9791142.
14. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-90. 10.1016/S0140-6736(98)06193-5, 9683207.
15. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930-7. 10.1001/jama.279.12.930, 9544767.
16. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-11. 10.1056/NEJM199807303390504, 9682043.
17. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-11.
18. Assefa Y, Jerene D, Lulseged S, Ooms G, Van Damme W. Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects. PLoS Med 2009, 6(4):e1000056. 10.1371/journal.pmed.1000056, 2667265, 19399154.
19. Ministry of Health of Ethiopia Guideline for Implementation of Antiretroviral Therapy in Ethiopia, Addis Ababa Ethiopia. 2005, Ministry of Health of Ethiopia.
20. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339(5):307-11. 10.1056/NEJM199807303390504, 9682043.
21. Amberbir A, Woldemichael K, Getachew S, et al. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008, 8:265. 10.1186/1471-2458-8-265, 2518153, 18667066.
22. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, Spurrier J, Vermund SH. Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr 2008, 47(5):615-22. 10.1097/QAI.0b013e318165dc25, 2743102, 18209678.
23. Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates among people living with HIV/AIDS on highly active antiretroviral therapy in Addis Ababa, Ethiopia. EMJ 2006, 44(2):237-244.
24. Markos E, Worku A, Davey G. Adherence to ART in PLWHA at Yirgalem Hospital, South Ethiopia Ethiop. J Health Dev 2008, 22(2):174-179.
25. Mengesha A, Worku A. Assessment of antiretroviral treatment among HIV infected persons in the Ministry of Defense Hospitals. AAU; MPH Thesis 2005,
26. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30(suppl 2):S171-S176. 10.1086/313849, 10860902.
27. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001, 161:1962-1968. 10.1001/archinte.161.16.1962, 11525698.
28. Wegner N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999,
29. Weiser S, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34:281-288. 10.1097/00126334-200311010-00004, 14600572.
30. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17:1369-1375. 10.1097/00002030-200306130-00011, 12799558.
31. Torheim LE, Ouattara F, Diarra MM, Thiam FD, Barikmo I, Hatløy A, Oshaug A. Nutrient adequacy and dietary diversity in rural Mali: association and determinants. Eur J Clin Nutr 2004, 58(4):594-604. 10.1038/sj.ejcn.1601853, 15042127.
32. Schonnesson LN, Diamond WPM, Michael R, et al. Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up. AIDS Care 2006, 18(3):246-253.
33. Bonolo PF, César CC, Acurcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS 2005, 19(suppl 4):s5-s13. 10.1097/01.aids.0000191484.84661.2b, 16249654.
34. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000, 23(5):386-95.
35. Brigido L, Rodrigues R, Casseb J, Oliveira D, Rossetti M, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS 2001, 11:587-593.
36. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991, 32:1161-7. 10.1016/0277-9536(91)90093-R, 2068599.
37. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001, 26(1):82-92.
38. Gao X, Nau DP, Rosenbluth SA, et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000, 12:387-98. 10.1080/09540120050123783, 11091771.
39. Rougemont M, Stoll BE, Elia N, Ngang P. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther 2009, 6:21. 10.1186/1742-6405-6-21, 2770068, 19821997.
40. Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology 2008, 5:13. 10.1186/1742-4690-5-13, 2267456, 18241330.
41. Grant E, Logie D, Masura M, Gorman D, Murray SA. Factors facilitating and challenging access and adherence to antiretroviral therapy in a township in the Zambian Copper belt: a qualitative study. AIDS Care 2008, 20(10):1155-60. 10.1080/09540120701854634, 19012078.
42. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS 2004, 18:385/93.
43. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004, 23(2):207-18. 10.1037/0278-6133.23.2.207, 15008666.
44. Stirratt MJ, Remien RH, Smith A, Copeland OQ, Dolezal C, Krieger D, . SMART Couples Study Team The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS Behav 2006, 10(5):483-93. 10.1007/s10461-006-9106-6, 16721505, SMART Couples Study Team.
45. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clinical Care 1997, 9(7):51-53.
46. Motashari F, et al. Acceptance and adherence with HAART therapy among HIV infected women in a correctional facility. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 18:341-348.
47. Murphy DA, Marelich WD, Hoffman D, et al. Predictors of Antiretroviral Adherence. AIDS Care 2004, 16:471-484. 10.1080/09540120410001683402, 15203415.
48. Fong OW, Ho CF, Fung LY, Lee FK, Tse WH, Yuen CY, Sin KP, Wong KH. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med 2003, 4(2):133-8. 10.1046/j.1468-1293.2003.00147.x, 12702134.
49. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr 2008, 8:34. 10.1186/1471-2431-8-34, 2533648, 18771599.